{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-009184","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.000691+00:00","generated_at":"2026-06-17T06:37:02.751597+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"SAB Biotherapeutics appoints Erick Lucera, former AVEO CFO, to Board of Directors","bullets":["Erick Lucera appointed to SAB Biotherapeutics Board effective April 4, 2023; term until next annual meeting.","Lucera most recently served as CFO of AVEO Oncology through its acquisition by LG Chem; prior CFO at Valeritas and Viventia Bio.","With 30+ years in biotech/med device finance, he brings experience in corporate finance, M&A, and public offerings.","Compensation consistent with other non-employee directors as described in the 2022 proxy statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-009184","json":"https://secwatch.observer/filing/0001437749-23-009184.json","markdown":"https://secwatch.observer/filing/0001437749-23-009184.md","text":"https://secwatch.observer/filing/0001437749-23-009184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923009184/0001437749-23-009184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923009184/sabs20230403_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:37:02.751597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ed00ce039","claim":"Erick Lucera was appointed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"the Board subsequently appointed, Mr. Erick Lucera to serve as a director of the Company, effective as of April 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923009184/0001437749-23-009184-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}